323 related articles for article (PubMed ID: 25746294)
1. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
[TBL] [Abstract][Full Text] [Related]
2. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
[TBL] [Abstract][Full Text] [Related]
5. A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
Kroll R; Seidman L; Ricciotti N; Howard B; Weiss H
Eur J Contracept Reprod Health Care; 2015; 20(4):249-58. PubMed ID: 25522805
[TBL] [Abstract][Full Text] [Related]
6. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
[TBL] [Abstract][Full Text] [Related]
7. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
8. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
9. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L; Kunz M; Marr J
Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
[TBL] [Abstract][Full Text] [Related]
10. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.
Duijkers IJ; Heger-Mahn D; Drouin D; Skouby S
Eur J Contracept Reprod Health Care; 2015; 20(6):419-27. PubMed ID: 26073333
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Duijkers IJ; Klipping C; Zimmerman Y; Appels N; Jost M; Maillard C; Mawet M; Foidart JM; Coelingh Bennink HJ
Eur J Contracept Reprod Health Care; 2015; 20(6):476-89. PubMed ID: 26394847
[TBL] [Abstract][Full Text] [Related]
12. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
Mulders TM; Dieben TO
Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
14. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function.
Duijkers I; Klipping C; Kinet V; Jost M; Bastidas A; Foidart JM
Contraception; 2021 Jun; 103(6):386-393. PubMed ID: 33689786
[TBL] [Abstract][Full Text] [Related]
15. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
16. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate.
Rible RD; Taylor D; Wilson ML; Stanczyk FZ; Mishell DR
Contraception; 2009 Mar; 79(3):182-8. PubMed ID: 19185670
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
[TBL] [Abstract][Full Text] [Related]
18. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
[TBL] [Abstract][Full Text] [Related]
19. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Klipping C; Duijkers I; Trummer D; Marr J
Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
Westhoff CL; Reinecke I; Bangerter K; Merz M
Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
